Steven Cohen’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.99M Buy
+136,181
New +$1.29M ﹤0.01% 2423
2026
Q2
– Sell
-1,149,325
Closed -$4.01M – 3925
2026
Q1
$4.01M Buy
1,149,325
+172,818
+18% +$622K 0.01% 1858
2025
Q4
$3.34M Buy
+976,507
New +$4.36M ﹤0.01% 2128
2023
Q3
– Sell
-3,959
Closed -$25.6K – 2407
2023
Q2
$25.6K Buy
+3,959
New +$27K ﹤0.01% 1743
2021
Q4
– Sell
-272,984
Closed -$5.47M – 1059
2021
Q3
$5.47M Buy
+272,984
New +$4.83M 0.02% 643
2021
Q1
– Sell
-55,000
Closed -$2.21M – 930
2020
Q4
$2.21M Buy
+55,000
New +$2.52M 0.01% 715

Other funds holding ABCL

Steven Cohen's ABCL Position: Q3 2026 in Review

Steven Cohen opened a new position in AbCellera Biologics (ABCL) in Q3 2026: 136,181 shares worth $1.99M. The stake represents ﹤0.01% of the portfolio and ranks #2423 among its holdings. This is a return to the name: Steven Cohen previously reported a position in ABCL as recently as Q1 2026.

Steven Cohen first reported a position in ABCL in Q4 2020 and has held it in 6 quarters since. The position peaked at $5.47M in Q3 2021. 163 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • Steven Cohen held 136,181 shares of AbCellera Biologics worth $1.99M as of Q3 2026.
  • AbCellera Biologics was a new Steven Cohen position in Q3 2026.
  • AbCellera Biologics made up ﹤0.01% of Steven Cohen's portfolio in Q3 2026, its #2423 holding.
  • Steven Cohen first reported a position in AbCellera Biologics in Q4 2020 and has held it in 6 quarters since.
  • Steven Cohen's AbCellera Biologics position peaked at $5.47M in Q3 2021.
  • 163 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.